Bill Amendment: IL HB3605 | 2025-2026 | 104th General Assembly

NOTE: For additional amemendments please see the Bill Drafting List

---

Bill Title: INS-GENETIC TESTING & SCREEN

Status: 2026-06-01 - Rule 3-9(a) / Re-referred to Assignments [HB3605 Detail]

Download: Illinois-2025-HB3605-House_Amendment_002.html

---

Rep. Camille Y. Lilly

Filed: 3/16/2026

 

 

 

10400HB3605ham002 LRB104 09298 BAB 35578 a
AMENDMENT TO HOUSE BILL 3605
AMENDMENT NO. ______. Amend House Bill 3605, AS AMENDED,
by replacing everything after the enacting clause with the
following:
"Section 5. The Illinois Insurance Code is amended by
changing Section 356u.10 as follows:
(215 ILCS 5/356u.10)
Sec. 356u.10. Genetic testing and evidence-based
screenings for an inherited gene mutation.
(a) As used in In this Section: ,
"Cost sharing" means a deductible, coinsurance, copayment,
or any similar out-of-pocket expense.
"Evidence-based cancer screening" means evidence-based
cancer screening modalities in accordance with the most recent
version of the National Comprehensive Cancer Network clinical
practice guidelines.

10400HB3605ham002 - 2 - LRB104 09298 BAB 35578 a
"Genetic genetic testing for an inherited mutation" means
germline multi-gene testing for an inherited mutation
associated with an increased risk of cancer in accordance with
evidence-based, clinical practice guidelines.
(b) A group policy of accident and health insurance or
managed care plan that is amended, delivered, issued, or
renewed after January 1, 2027 2026 shall provide coverage for
clinical genetic testing for an inherited gene mutation for
individuals with a personal or family history of cancer, as
recommended by a health care professional in accordance with
current evidence-based clinical practice guidelines,
including, but not limited to, the current version of the
National Comprehensive Cancer Network clinical practice
guidelines. The coverage shall limit the total amount that a
covered person is required to pay for a clinical genetic test
under this subsection to an amount not to exceed $50, except
for services for which cost sharing is prohibited under 42
U.S.C. 300gg-13. This subsection (b) shall not apply to
coverage of genetic testing to the extent such coverage would
disqualify a high-deductible health plan from eligibility for
a health savings account pursuant to Section 223 of the
Internal Revenue Code.
(c) For individuals with a genetic test that is positive
for an inherited mutation associated with an increased risk of
cancer, coverage required under this Section shall include any
evidence-based screenings, as recommended by a health care

10400HB3605ham002 - 3 - LRB104 09298 BAB 35578 a
professional in accordance with current evidence-based
clinical practice guidelines, including, but not limited to,
the current version of the National Comprehensive Cancer
Network clinical practice guidelines, to the extent that the
management recommendation is not already covered by the
policy. , except that coverage for evidence-based screenings
under this subsection (c) may be subject to a deductible,
coinsurance, or other cost-sharing limitation so long as the
limitation is not greater than that required for other related
cancer risk management benefits covered under the policy. In
this subsection, "evidence-based cancer screenings" means
medically recommended evidence-based screening modalities in
accordance with current clinical practice guidelines.
(d) The coverage provided in subsections (b) and (c) shall
be provided without cost sharing, except for services for
which cost sharing is prohibited under 42 U.S.C. 300gg-13.
Subsections (b) and (c) do not apply to the extent that
providing such coverage would disqualify a high-deductible
health plan from eligibility for a health savings account
pursuant to Section 223 of the Internal Revenue Code.
(Source: P.A. 103-914, eff. 1-1-25.)".